Hair loss on GLP-1 medicines: what the labels and studies show

What the drug labels report

The FDA-approved labels count side effects reported in the weight-loss trials. Three of them list hair loss in the trial tables.

Read on DailyMed in October 2026 from the label versions marked Revised 8/2026 (Zepbound), 6/2026 (Wegovy) and 7/2026 (Foundayo). The Wegovy tablet section gives no separate hair loss rate. A label rate counts reports in trials. It does not prove the medicine caused each case.

What the labels of other GLP-1 medicines say

The Saxenda and Mounjaro labels do not list hair loss in their trial tables. Each mentions alopecia once, in the section on reports made after approval, with no rate given, and says the frequency of those reports cannot be reliably estimated. The Atlas read those two labels in October 2026. It did not check Ozempic's label for this page.

What newer studies found

Labels come from trials that were not built to study hair. Since 2024, several studies have looked at it directly. They differ in design, and none can prove cause.

A figure of seven in ten people comes from one survey, not from a trial. In that survey of 152 current and former users in Saudi Arabia, 70.4% said they had noticed hair shedding. The people who answered chose to take part, they reported on themselves, and there was no comparison group.

Why hair may shed

The leading explanation is a kind of shedding called telogen effluvium. Hair follows a cycle, and a physical stress can push many hairs into the resting phase at once. They then fall out a few months later. Rapid weight loss is a known trigger. A 2026 dermatology commentary names it as one potential mechanism with these medicines, and a 2026 narrative review says shedding is driven mainly by the size and speed of weight loss rather than by drug toxicity. Neither is a test of the idea. The labels use similar language, saying hair loss was associated with weight reduction.

Evidence from weight-loss surgery points the same way. A 2021 review of 18 studies and 2,538 people found hair loss after bariatric surgery in about 57% of people (95% CI 42% to 71%), less often as follow-up grew longer. It was more common in younger people and in those with lower folic acid and ferritin (stored iron) levels. These were not people on GLP-1 medicines, so the findings may not carry over.

Whether the medicines affect hair follicles in some way beyond weight loss has not been established. Facial changes after weight loss raise a similar question about the drug versus the weight loss, covered on the Ozempic face page.

How long does it last?

The Atlas found no study that followed hair regrowth over time in people on these medicines. A 2026 narrative review calls the shedding mostly temporary and reversible but gives no timeframe. The Saudi survey reported that 37.7% said shedding resolved after they stopped treatment. That is self-reported, and stopping the medicine also changes weight and eating.

In the bariatric surgery review, hair loss became less common with longer follow-up. That suggests shedding after rapid weight loss often eases, but it says nothing certain about GLP-1 medicines.

What has been tested for it

The Atlas found no published randomized trial of a supplement, a hair medicine or a diet change for hair loss in people taking GLP-1 medicines. A commentary in 2026 also says no prospective, controlled studies have looked at the question.

Two small studies are registered and have no results. One (NCT07484061) is a placebo-controlled test of a drinkable supplement in 40 women over 35 who are starting or recently started a GLP-1 or GIP medicine, with a hair shedding scale as its main measure at day 180. The other (NCT07783113) is an open-label study with no comparison group, in 48 women in Brazil with shedding linked to semaglutide or tirzepatide. Both are sponsored by companies that make supplements.

What people report

In online communities, people describe shedding that began a few months after they started, handfuls of hair in the shower and worry about thinning. The themes people commonly describe are eating more protein, trying supplements and asking a dermatologist.

None of this was measured in people on these medicines, and posts cannot separate the effect of the medicine from the weight loss, low intake or another cause. It is here because it is common, not because any remedy works.

When people raise it with a clinician

Three 2026 papers address this. The dermatology commentary says patients should be told about the possible risk and monitored for hair loss. The narrative review recommends early counseling. The meta-analysis recommends counseling, attention to nutrition and avoiding premature stopping of the medicine. The commentary was funded by a skin-care company whose employees are among its authors. These are the authors' views and not tested instructions, and whether to raise hair loss, or change anything, is a conversation for you and a prescriber or dermatologist.

A European safety review is under way

The agenda for the European Medicines Agency's safety committee meeting of September 28 to October 1, 2026 lists a signal of alopecia for liraglutide products, including Saxenda, marked for adoption of a recommendation. An agenda is not a decision. The Atlas had not found the outcome when this page was written.

Quick answers

Do Wegovy, Zepbound and Foundayo cause hair loss?

Their labels list hair loss as a side effect reported in trials and say it was associated with weight reduction. Newer studies suggest a higher risk than comparison groups, but they cannot show that the medicine itself is the cause.

How common is hair loss on Zepbound?

The label table shows 4% to 5% of people on Zepbound reported hair loss against 1% on placebo. The label says 7.1% of women and 0.5% of men on Zepbound reported it.

How common is hair loss on Wegovy?

The injection label shows 3% on the 2.4 mg dose and 6% on the 7.2 mg dose, against 1% on placebo. The label gives no separate rate for the tablets.

Why do some surveys show far higher numbers than the labels?

Label rates come from trials that counted reports among all participants. A survey of volunteers asks people who may have noticed shedding to reply, and it has no comparison group. Neither number is a precise rate for any one person.

Is the hair loss permanent?

That is not established. A 2026 review calls it mostly temporary but gives no timeframe, and one survey reported that 37.7% said shedding resolved after they stopped treatment.

Is it the medicine or the weight loss?

That is not known. The labels link it to weight reduction, and rapid weight loss is the leading explanation, but studies have not separated the two.

Does biotin or another supplement prevent it?

The Atlas found no published trial in people on these medicines. Two small studies of supplements are registered and have no results.

Does Ozempic or Mounjaro cause hair loss?

The Mounjaro label mentions alopecia once, among reports after approval, with no rate. The Atlas did not check Ozempic's label for this page.

Should I stop my medicine because of hair loss?

That is a decision for you and your prescriber. Stopping brings its own changes, which the weight regain page describes.

Questions to ask

• Does my hair loss look like shedding after weight loss, or could it be something else, such as thyroid or iron problems?
• Which blood tests, if any, make sense for me?
• Are my protein and nutrient intake enough?
• Would seeing a dermatologist help?
• If the shedding worries me, what are my options besides stopping?

What is still unknown

• The trials behind the labels were not built to study hair, and the Atlas read the label tables, not the tables inside each trial paper.
• Whether the medicines affect hair beyond the effect of weight loss has not been tested.
• The Tang study compared diabetes medicines in people with type 2 diabetes. It did not compare people with similar weight loss.
• How long shedding lasts in people on these medicines has not been measured in the sources the Atlas found.
• Whether any supplement or treatment helps has not been tested in a published controlled trial.
• Label text changes. The figures here are from versions read in October 2026.